Bionano Enterprise Value Over E B I T D A from 2010 to 2024

BNGO Stock  USD 0.76  0.03  3.66%   
Bionano Genomics Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to drop to -0.83. During the period from 2010 to 2024, Bionano Genomics Enterprise Value Over EBITDA quarterly data regression pattern had range of 9.7872 and standard deviation of  2.81. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(0.79)
Current Value
(0.83)
Quarterly Volatility
2.80703218
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano main balance sheet or income statement drivers, such as Tax Provision of 65.1 K, Interest Income of 3.5 M or Depreciation And Amortization of 14.4 M, as well as many exotic indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.005 or PTB Ratio of 0.64. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.
  
This module can also supplement Bionano Genomics' financial leverage analysis and stock options assessment as well as various Bionano Genomics Technical models . Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Latest Bionano Genomics' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Bionano Genomics over the last few years. It is Bionano Genomics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bionano Genomics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Pretty Stable
   Enterprise Value Over E B I T D A   
       Timeline  

Bionano Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(2.54)
Coefficient Of Variation(110.52)
Mean Deviation1.87
Median(1.66)
Standard Deviation2.81
Sample Variance7.88
Range9.7872
R-Value(0.28)
Mean Square Error7.82
R-Squared0.08
Significance0.31
Slope(0.18)
Total Sum of Squares110.31

Bionano Enterprise Value Over E B I T D A History

2024 -0.83
2023 -0.79
2022 -3.29
2021 -10.58
2020 -7.76
2019 -0.82
2018 -1.4

About Bionano Genomics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bionano Genomics income statement, its balance sheet, and the statement of cash flows. Bionano Genomics investors use historical funamental indicators, such as Bionano Genomics's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Bionano Genomics investors may use each financial statement separately, they are all related. The changes in Bionano Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bionano Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bionano Genomics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bionano Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(0.79)(0.83)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bionano Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bionano Genomics' short interest history, or implied volatility extrapolated from Bionano Genomics options trading.

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

  0.7KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.83DRMA Dermata Therapeutics Financial Report 9th of May 2024 PairCorr

Moving against Bionano Stock

  0.78YS YS BiopharmaPairCorr
  0.71FUSN Fusion PharmaceuticalsInc Financial Report 9th of May 2024 PairCorr
  0.7DSGN Design Therapeutics Financial Report 14th of May 2024 PairCorr
  0.67HCM HUTCHMED DRCPairCorr
  0.65ELYM Eliem TherapeuticsPairCorr
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:
Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
CEOs Directory
Screen CEOs from public companies around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.81)
Revenue Per Share
1.058
Quarterly Revenue Growth
0.305
Return On Assets
(0.33)
Return On Equity
(1.35)
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.